Analysis of the cost-effectiveness of using vonoprazan–amoxicillin–clarithromycin triple therapy for first-line <i>Helicobacter pylori</i> eradication

Kajihara, Yusaku; Shimoyama, Tadashi; Mizuki, Ichiro

doi:10.1080/00365521.2016.1250157

Cited by 26 publications

(31 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A total of 133 studies were identified in the PubMed, EMBASE, and Cochrane Library databases. After reviewing the titles, abstracts, and full texts, we ultimately included 14 studies in the meta‐analysis. The detailed selection process is shown in Figure .…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Review: A Japanese population‐based meta‐analysis of vonoprazan versus PPI for Helicobacter pylori eradication therapy: Is superiority an illusion?

et al. 2017

View full text Add to dashboard Cite

show abstract

Section: Resultsmentioning

confidence: 99%

“…The detailed selection process is shown in Figure . In the 12 included studies, there are 2 well‐designed RCTs and 12 retrospective studies . The basic characteristics of all of the included studies are presented in Table .…”

Section: Resultsmentioning

confidence: 99%

Review: A Japanese population‐based meta‐analysis of vonoprazan versus PPI for Helicobacter pylori eradication therapy: Is superiority an illusion?

et al. 2017

View full text Add to dashboard Cite

show abstract

“…One cost‐effectiveness study was carried out which showed in a population where vonoprazan triple therapy achieved 94.6% eradication rates compared to 86.7% for PPI‐based therapy that the vonoprazan option cost 1155.4 Japanese yen (approx. €10) higher than PPI . On this basis, the cost‐effectiveness ratio of vonoprazan was less than PPI (360.1 vs 379.4, Japanese yen per percent) and incremental cost‐effectiveness ratio of vonoprazan was 147.0 JPY/1.28 Euro per percent.…”

Section: Vonoprazanmentioning

confidence: 83%

“…€10) higher than PPI. 103 On this basis, the costeffectiveness ratio of vonoprazan was less than PPI (360.1 vs 379.4, Japanese yen per percent) and incremental cost-effectiveness ratio of vonoprazan was 147.0 JPY/1.28 Euro per percent.…”

Section: Vonoprazanmentioning

confidence: 95%

“…year where this agent is approved for use, all of which have found superiority for vonoprazan over PPI in triple therapy formats. [100][101][102][103][104][105][106][107][108][109][110][111] This is summarized in Table 2. It is noteworthy, however, that vonoprazan has been tested in triple therapies only and not in other regimens such as quadruple therapy, sequential therapy, or with bismuth.…”

Section: Vonoprazanmentioning

confidence: 99%

See 1 more Smart Citation

Treatment of Helicobacter pylori infection 2017

et al. 2017

View full text Add to dashboard Cite

Over the last decade, it has been widely reported that the success of Helicobacter pylori eradication treatment is falling. A steady decline was observed in the number of patients achieving eradication with standard first-line triple therapy of two antibiotics and a proton pump inhibitor [1][2][3]. It now appears that the first-line eradication therapies most commonly used in everyday clinical practice fall considerably short of the 80% intention-to-treat (ITT) eradication rates that are considered the minimal acceptable levels as recommended in the Maastricht guidelines [4]. Interestingly, two studies emerged from Asian centers in the last 12 months, which show that, in this part of the world at least, eradication levels using standard therapies remain close to 80%. A Malaysian study showed a standard 1-week pantoprazole, amoxycillin, and clarithromycin regimen to be well tolerated and highly efficacious with a per-protocol eradication rate of 84% [5]. A Japanese study showed remarkably consistent per-protocol eradication rates from 2001 to 2009 fluctuating between 75 and 78% for standard 7-day triple-therapy regimens [6]. A limit of many studies especially those including clarithromycin or levofloxacin is that H. pylori susceptibility to the drugs, which is the main prediction of failure, was not tested. LevofloxacinThe use of levofloxacin as a first-line therapy has been examined in great depth in the last year. Levofloxacin may be used as a substitute for clarithromycin in either a standard triple or sequential regimen. A large study comparing the antibiotics in either regimen shows a clear advantage to levofloxacin in both combinations. Per-protocol cure rates for triple therapy were 66% for omeprazole-clarithromycin-amoxycillin compared with 83% for omeprazole-levofloxacin-amoxycillin and 81% for omeprazole-amoxycillin-clarithromycin-metronidazole vs 85% for omeprazole-amoxycillin-levofloxacinmetronidazole, with no difference in compliance rates or adverse events [7]. It has been proposed that sequential levofloxacin-based regimens are of most benefit in areas where clarithromycin resistance is in excess of 15%, and another study in such an area showed eradication rates of 81% with clarithromycin sequential therapy compared with 96% with levofloxacin sequential therapy. A third arm in this study looked at the dose of levofloxacin required and illustrated no benefit in increasing the dose from 250 to 500 mg [8]. Indeed, another study went so far as to suggest that once-daily dosing of a levofloxacin-based triple regimen may be as efficacious as twice daily [9]. The literature from Asia also seems to support levofloxacin as a good alternative first-line therapy. A study on a triple regimen showed per-protocol eradication rates of 78% for standard clarithromycin-containing therapies compared with 83% for a levofloxacin-based regimen [10]. Another study from the Middle East looked at whether combining clarithromycin and levofloxacin in the same regimen could be Keywords Peptic ulcer disease, resistance, compli...

show abstract

Current status of gastric and oral infection/diseases caused by Helicobacter pylori

Noiri

Nagata

2023

Oral Science International

View full text Add to dashboard Cite

Helicobacter pylori is found in the stomach, which is its optimal habitat, and is considered an important factor in various serious diseases, including stomach cancer. The World Health Organization has identified H. pylori as a causative agent of gastric cancer, as confirmed by animal experiments in rodents. The fact that H. pylori can live in the harsh environment of stomach acid was the greatest hindrance to the discovery of H. pylori. It was not so long ago, in 1983, that it was successfully isolated and cultured. Subsequently, H. pylori eradication therapy was established, and it became possible to control gastric cancer to some extent. However, the mechanism, route, and mode of H. pylori infection still remain unclear. Furthermore, currently, the prevention of first‐episode gastric cancer and control of recurrent gastric cancer are not perfect. One of the reasons for this may be that the status of H. pylori in the oral cavity, which is the entry point for the organism (the beginning of the digestive system: the first route of infection), is still unknown. Therefore, we reviewed the current status of H. pylori infection in the stomach and oral cavity, focusing on (1) the mechanism of infection, (2) pathogenic factors, (3) the actual status of eradication therapy, and (4) control strategies.

show abstract

Analysis of the cost-effectiveness of using vonoprazan–amoxicillin–clarithromycin triple therapy for first-line Helicobacter pylori eradication

Abstract: VPZ/AC was more cost-effective than RPZ/AC as first-line therapy for H. pylori eradication.

Cited by 26 publications

References 12 publications

Review: A Japanese population‐based meta‐analysis of vonoprazan versus PPI for Helicobacter pylori eradication therapy: Is superiority an illusion?

Review: A Japanese population‐based meta‐analysis of vonoprazan versus PPI for Helicobacter pylori eradication therapy: Is superiority an illusion?

Treatment of Helicobacter pylori infection 2017

Current status of gastric and oral infection/diseases caused by Helicobacter pylori

Contact Info

Product

Resources

About